Trial Outcomes & Findings for Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear (NCT NCT01379768)

NCT ID: NCT01379768

Last Updated: 2013-03-08

Results Overview

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA). Different types of white blood cells (leukocytes) were identified, which included neutrophils, monocytes, and lymphocytes. The total amount of leukocytes for contact lens wearers and non-lens wearers is presented. Potential differences in leukocyte count between lens wearers and non-lens wearers may indicate a different immune response.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

65 participants

Primary outcome timeframe

Week 5

Results posted on

2013-03-08

Participant Flow

Study participants were recruited from one study center located in Canada.

Participant milestones

Participant milestones
Measure
Lotrafilcon A
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Overall Study
STARTED
23
22
20
Overall Study
COMPLETED
20
21
20
Overall Study
NOT COMPLETED
3
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Lotrafilcon A
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Overall Study
Adverse Event
1
1
0
Overall Study
Lost to Follow-up
2
0
0

Baseline Characteristics

Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lotrafilcon A
n=23 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=22 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=20 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Total
n=65 Participants
Total of all reporting groups
Age, Customized
22 years
n=5 Participants
23.5 years
n=7 Participants
23.5 years
n=5 Participants
23 years
n=4 Participants
Sex: Female, Male
Female
17 Participants
n=5 Participants
19 Participants
n=7 Participants
13 Participants
n=5 Participants
49 Participants
n=4 Participants
Sex: Female, Male
Male
6 Participants
n=5 Participants
3 Participants
n=7 Participants
7 Participants
n=5 Participants
16 Participants
n=4 Participants
Region of Enrollment
Canada
23 participants
n=5 Participants
22 participants
n=7 Participants
20 participants
n=5 Participants
65 participants
n=4 Participants

PRIMARY outcome

Timeframe: Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA). Different types of white blood cells (leukocytes) were identified, which included neutrophils, monocytes, and lymphocytes. The total amount of leukocytes for contact lens wearers and non-lens wearers is presented. Potential differences in leukocyte count between lens wearers and non-lens wearers may indicate a different immune response.

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=20 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=19 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=20 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Leukocyte Population
583187 Leukocytes
Standard Deviation 832636
420345 Leukocytes
Standard Deviation 355940
738140 Leukocytes
Standard Deviation 609853

PRIMARY outcome

Timeframe: Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA) and analyzed on a flow cytometer. CD54 is a protein typically found in the cell membrane of leukocytes, which up-regulates during inflammation and promotes cell adhesion. Cell adhesion response is reported as a ratio of stimulated to non-stimulated samples.

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=20 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=18 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=19 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Relative Cell Adhesion Response of Polymorphonuclear Leukocytes (PMNs)
1.1 Ratio
Standard Deviation 0.2
1.2 Ratio
Standard Deviation 0.2
1.1 Ratio
Standard Deviation 0.1

PRIMARY outcome

Timeframe: Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA) and analyzed on a flow cytometer. Oxidative response is reported as a ratio of activated to non-activated samples. DCF (dichlorofluorescein diacetate) is a molecular probe that measures the oxidative burst. Upon stimulation, the PMNs synthesize reactive oxygen species, such as superoxide or hydrogen peroxide, which is detected by the probe. Differences in the oxidative response between contact lens wearers and non-lens wearers is indicated by a shift in the ratio (stimulated/unstimulated).

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=20 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=19 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=20 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Relative Oxidative Response of Polymorphonuclear Leukocytes (PMNs)
1.2 Ratio
Standard Deviation 0.5
1.7 Ratio
Standard Deviation 1.1
1.3 Ratio
Standard Deviation 0.6

PRIMARY outcome

Timeframe: Week 1, Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA). Different types of white blood cells (leukocytes) were identified, which included neutrophils, monocytes, and lymphocytes. The difference between total leukocytes for contact lens wearers and non-lens wearers (Week 5 minus Week 1) is presented.

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=19 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=19 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=19 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Change From Week 1 in Leukocyte Population at Week 5
-1377 Leukocytes
Standard Deviation 453,119
-95301 Leukocytes
Standard Deviation 632752
122316 Leukocytes
Standard Deviation 519976

PRIMARY outcome

Timeframe: Week 1, Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA) and analyzed on a flow cytometer. Cell adhesion response is reported as a ratio of activated to non-activated samples. The difference between the ratio data for contact lens wearers and non-lens wearers (Week 5 minus Week 1) is presented.

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=18 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=15 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=16 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Change From 1 Week in Relative Cell Adhesion Response of PMNs at Week 5
-0.01 Ratio
Standard Deviation 0.23
0.00 Ratio
Standard Deviation 0.24
-0.01 Ratio
Standard Deviation 0.20

PRIMARY outcome

Timeframe: Week 1, Week 5

Population: This reporting group includes all participants who completed the study per protocol.

A tear sample was collected after 8 hours of sleep using an ocular surface cell collection apparatus (OSCCA) and analyzed on a flow cytometer. Oxidative response is reported as a ratio of activated to non-activated samples. The difference between the ratio data for contact lens wearers and non-lens wearers (Week 5 minus Week 1) is presented.

Outcome measures

Outcome measures
Measure
Lotrafilcon A
n=19 Participants
Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
Lotrafilcon B
n=18 Participants
Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
No Lens Wear
n=19 Participants
No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
Change From Week 1 in Relative Oxidative Response of PMNs at Week 5
0.05 Ratio
Standard Deviation 0.94
0.24 Ratio
Standard Deviation 1.20
-0.19 Ratio
Standard Deviation 0.58

Adverse Events

Lotrafilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Lotrafilcon B

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No Lens Wear

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Director of Alcon Clinical, Atlanta

Alcon Research

Phone: 1-800-241-7629

Results disclosure agreements

  • Principal investigator is a sponsor employee For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.
  • Publication restrictions are in place

Restriction type: OTHER